Pubmed- Azathioprine-induced alopecia: rare adverse event early marker of myelotoxicity - IBD Reporter Newsfeed - IBD Support Group Forums -


Jump to content

- - - - -

Pubmed- Azathioprine-induced alopecia: rare adverse event early marker of myelotoxicity

  • Please log in to reply
No replies to this topic

#1 Health Reporter

Health Reporter


  • RSS
  • PipPipPipPip
  • 20847 posts
  • Country:United States

Posted 14 September 2021 - 02:42 PM


Rev Esp Enferm Dig. 2021 Sep 14. doi: 10.17235/reed.2021.8175/2021. Online ahead of print.


Azathioprine is a drug widely used to treat patients with inflammatory bowel disease, with not an inconsiderable frequency of adverse events. Among these, myelotoxicity is one of the most serious. For some time, the existence of specific genetic variations of the gene encoding thiopurine-methyltransferase that affect enzymatic activity and produce alterations in thiopurine metabolism that translate into a higher frequency of adverse events in these patients has been known. It has recently been observed that patients carrying certain genetic variations in the nudix hydrolase gene also present a higher rate of adverse events induced by azathioprine, mainly related to leukopenia and alopecia, the latter behaving as an early clinical marker of myelotoxicity. These genetic variants are more common in the Asian population. We present the case of a European patient with azathioprine-induced alopecia and leukopenia whose genetic analysis confirmed that she had one of the genetic alterations associated with the appearance of these adverse events.

PMID:34517716 | DOI:10.17235/reed.2021.8175/2021


View the full article


© Copyright 1995-2014 IBD Support All rights reserved.

About Us | Contact Us | Advertise With Us | Disclaimer | Terms of Service | Crisis Resources

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information: verify here